SGHT

Sight Sciences, Inc.

$10.75

-2.36%
SectorHealthcareIndustryMedical DevicesCountryUnited States

Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases in the United States. The company operates in two segments, Surgical Glaucoma and Dry Eye. It offers OMNI, a surgical system family of products, such as OMNI Ergo for the catheterization and transluminal viscodilation of Schlemm's canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma; and OMNI EDGE, an implant-free and minimally invasive glaucoma surgery technology.

Source: Yahoo Finance
AI summary

Price & performance

1M+9.4%
3M+75.9%
YTD+30.5%
1Y+94.0%
52-week range—
Beta1.61
Full chart and returns against a benchmark

Q-Score

62/ 100

Quality against peers; 50 is the peer median.

Growth66
Risk52
Performance79
Valuation42
Profitability56
Leverage46
Sentiment60
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue$77.4M-3.1%
Net income-$38.4M
Net margin-49.7%+14.8 pts
Historical fundamentals

Revenue exposure

0%of revenue from outside the US
United States100%
Regions, segments, customers and suppliers

Valuation

SGHTIndustryP/E—29.61P/S6.763.49EV/EBITDA—18.38P/B12.163.39PEG——
Dividend yield0.00%
Every valuation metric

Earnings

Nov 4next report
EPS estimate$-0.13
Beats (last 4 quarters)—
Average surprise—
EPS revisions (30d)—
Every quarter against its estimate